Abstract:Background This study aimed to evaluate the visual and morphological outcomes of intravitreal anti-VEGF therapy and the recurrence for idiopathic choroidal neovascularization (ICNV). Methods This retrospective study included 35 patients (35 eyes) with ICNV from July 2012 to October 2017. All patients received 1 intravitreal anti-VEGF injection followed by pro re nata injections until there was no sign of ICNV activity. This was defined as the first follow-up period. To evaluate ICNV recurrence, we continued to follow-up 27 of the 35 patients for at least 2 years after the initial diagnosis, and the longest follow-up period was 5 years. Additional injection was performed when ICNV recurred. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded and morphological improvement in optical coherence tomography (OCT) was assessed. Parameters that affect prognosis and recurrence were analysed. Results The mean follow-up period was 168.0 ± 34.82 weeks. Mean BCVA improved from 56.20 ± 14.13 letters at baseline to 73.31 ± 12.57 letters ( P <0.01); Mean CRT decreased from 353.6 ± 98.70 μm at baseline to 273.1 ± 53.56 μm ( P < 0.001) at the end of the first follow-up period. Better baseline BCVA indicated a better morphological improvement ( P = 0.026) in OCT: the lesion had completely subsided with recovery of the foveal contour. Those with high baseline BCVA (more than 60 letters) showed significant resolution of CNV lesions ( P = 0.036). ICNV recurred in six patients (22.2%), 1 of whom experienced 2 recurrences. The mean timing of recurrence was 90.83 ± 49.02 weeks after diagnosis. There was no significant correlation between ICNV recurrence and the morphological improvement ( P = 0.633). The final BCVA in patients with recurrence did not differ from that in patients without recurrence ( P = 0.065). Conclusions Intravitreal anti-VEGF therapy on a pro re nata basis was effective for treating ICNV. High baseline BCVA indicated a better prognosis. Re-treatment with anti-VEGF could effectively lead to resolution of recurrent ICNV. Disease recurrence had no significant effect on final visual prognosis and had no correlation with the morphological improvement during treatment, suggesting that follow-up for subsequent monitoring should be performed in all ICNV patients.

Outcome of Intravitreal Bevacizumab for Idiopathic Choroidal Neovascularization in a Chinese Population

Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.

Changes in Vitreous VEGF, Bfgf and Fibrosis in Proliferative Diabetic Retinopathy after Intravitreal Bevacizumab.

Evaluation of Efficacy and Recurrence for Anti-Vascular Endothelial Growth Factor Therapy in Idiopathic Choroidal Neovascularization

Intravitreal anti-vascular endothelial growth factor in the treatment of idiopathic choroidal neovascularization:a retrospective analysis

Choroidal Response to Intravitreal Bevacizumab Injections in Treatment-Naïve Macular Neovascularization Secondary to Chronic Central Serous Chorioretinopathy

Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry

Idiopathic Choroidal Neovascularization: Intraocular Inflammatory Cytokines and the Effect of Intravitreal Ranibizumab Treatment

Effects of intravitreal Bevacizumab (Avastin) monotherapy in central retinal vein occlusion in young subjects

Experimental Study on the Inhibitory Effect of Bevacizumab on Choroidal Neovascularization in Rat

Comparison of anatomical and functional outcomes of treating myopic choroidal neovascularization with bevacizumab or ranibizumab

Meta-analysis of the Effect of Intravitreal Bevacizumab Versus Photodynamic Therapy in Myopic Choroidal Neovascularisation

Clinical observation of intravitreal injection with Bevacizumab for iris neovascularization

Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy.

Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy

Bevacizumab for Neovascular Age-Related Macular Degeneration in China.

Changes in Aqueous Concentrations of Various Cytokines after Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy

The clinical study on intravitreous injection of avastin for macular edema induced by branch retinal vein occlusion

Intravitreous bevacizumab(Avastin) therapy for diffuse diabetic macular edema

Effect of Intravitreal Injection of Anti VEGF Drugs on BCVA and Mferg Before and after Treatment for MCNV and ICNV

Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.